TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| S | %ret | 3 | 1 | 3 | -5 | 2 | -4 | -8 | -37 | -17 | -11 |
| S | %wins | 100 | 33 | 67 | 67 | 100 | 67 | 72 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11/16/18 19:16 | 11/15/18 | GTHX | G1 Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Phillips Barclay A | NC | O | SVP,CFO | S.d | -200 | 39.92 | 0 | -5 | -100 | 0 | D | ||||||||||||||
8/21/15 17:08 | 8/19/15 | NVAX | Novavax Inc | DE | Health | BioPrd | Biological Products, (No Diag | Phillips Barclay A | MD | O | SVP,CFO | S.m | -374 | 13.06 | 33 | -29 | -76 | 9 | D | 315 | 174 | 30 | 39 | 3 | 2 | -11 | -13 | -12 | -4 | -18 | -36 | -58 | -42 |
11/12/09 16:01 | 11/9/09 | MITI | Micromet, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Phillips Barclay A | MD | O | SVP , CF | S.d | -214 | 6.10 | 2 | -35 | -96 | 1 | M | 271 | 45 | 75 | 4 | 6 | 17 | 25 | 9 | -2 | 7 | -1 | 22 | -5 | 6 |
6/16/08 16:04 | 6/13/08 | ACOR | Acorda Therapeutics Inc | Health | BioPrd | Biological Products, (No Diag | Phillips Barclay A | NY | D | S | -7,120 | 30.30 | 33 | -235 | -27 | 641 | I | 827 | 67 | 66 | 65 | 42 | 47 | 3 | 0 | -1 | 3 | 8 | -11 | -47 | -14 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |